Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25183575 | 0.74 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL28951980 | 0.73 | EPHX1 (0.41) | EPHX1 | |
| SCHEMBL20959102 | 0.70 | — | — | |
| SCHEMBL19043848 | 0.67 | — | — | |
| SCHEMBL30039025 | 0.67 | — | — | |
| SCHEMBL1635078 | 0.65 | KMT2A (0.34) | SLC6A12SLC6A11 | |
| SCHEMBL26633759 | 0.65 | SLC9A1 (0.39) | — | |
| SCHEMBL1634028 | 0.64 | HRH3 (0.36) | — | |
| SCHEMBL1634106 | 0.64 | HRH3 (0.36) | — | |
| SCHEMBL1633724 | 0.64 | HRH3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | EPHX1 3913/4885SLC6A12 366/4885SLC6A11 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.